Biopharmaceutical stocks are targeting Crohn’s Disease in developing drugs in 2022. Research finds that this is a $13.7 billion market ripe for sector stock catalysts such as profit and dividends. CATALYSTS BIOTECH INVESTORS SHOULD MONITOR Here are catalysts for buying into biopharmaceutical stocks targeting the development of Crohn’s Disease drugs in 2022: — The market… Continue reading Biopharma Stocks Targeting Crohn’s Disease In $13.7 Billion Market (STAB, ARNA, GILD and RDHL)
Industry Report
Developing Biopharma Plays to Look at Now (STAB, MEIP, ABIO, AMPE, ZIVO, MREO)
Biopharmaceutical stocks have profitable catalysts in 2022. As a sector, the biopharma industry dropped in 2021 as COVID-19 declined. Now new opportunities are here. Why It Matters To Investors Here are catalysts for buying into biopharmaceutical stocks in 2022: — The COVID-19 pandemic has settled into an endemic. Drug candidates remain profit makers but they… Continue reading Developing Biopharma Plays to Look at Now (STAB, MEIP, ABIO, AMPE, ZIVO, MREO)
GENH To Benefit From Fast-Growing Hemp Market Valuation
Generation Hemp, Inc. (OTCMKTS: GENH) is one of the most diversified pure play hemp picks on the public markets. Last week, Research and Markets released a report stating “the global industrial hemp market size is expected to reach USD $16.75 billion by 2030, registering a CAGR of 16.8%.” GENH may be one of the largest… Continue reading GENH To Benefit From Fast-Growing Hemp Market Valuation
Alt. Agriculture Plays Set to Pop on Sanctions
GENH, RKDA, SNES, EVGN, CLXT, AGFS, VEGI Geopolitical concerns over the Russian invasion of Ukraine are just the latest in a string of macroeconomic events pushing Agriculture stocks higher. Supply chain problems, increasing energy costs, and rising global demand are creating higher commodity prices and thereby higher revenues for US agriculture. The United States Department… Continue reading Alt. Agriculture Plays Set to Pop on Sanctions
Biotech Pharmaceutical Sector Fights COVID-19
Biotech Pharmaceutical stocks are building profits in 2022 while developing more effective COVID-19 vaccines and treatments for variants. Investors may buy these stocks now as new drugs reach the market. Biotech Pharmaceutical analysts see the pandemic evolving into an endemic. Profits are ahead as global countries seek COVID-19 vaccines. Biotech R&D for COVID-19 specialty vaccines… Continue reading Biotech Pharmaceutical Sector Fights COVID-19
Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EXEL, MRK, JNJ)
Biopharmaceutical stocks are soaring this year. As a sector, the biopharma industry has grown 38% per year over the past three years. Sector stock revenues have grown cumulatively 10% annually and are seen repeating that performance for the next five years. Biopharma will be a $471.02 billion market by 2027, according to stocknews.com, growing at… Continue reading Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EXEL, MRK, JNJ)
Speculative Cyber Security Stocks Set To Pop as Russia Persists (MWWC, CTEK, SFET, LGMK, CSPI, BKYI)
As sanctions mount against Russia, it is anticipated that Putin’s response will come in the form of cyberwarfare. For that reason, cybersecurity stocks are on fire. There is a virtual cornucopia of cloud defenders for the discerning investor’s portfolio with major profit potential. This report will differentiate which software security securities are best suited… Continue reading Speculative Cyber Security Stocks Set To Pop as Russia Persists (MWWC, CTEK, SFET, LGMK, CSPI, BKYI)
Hemp Industry Growth Makes These Stocks Must-See (GENH, ACB, TLRY, CGC, IIPR)
The 2018 Farm Bill, made industrial hemp completely legal. Unlike cannabis, hemp is 100% federally legal. Cannabis stocks have fallen on hard times recently, however, hemp stocks should not have the same issues. Hemp yields lower amounts of THC the psychoactive compound found in recreational marijuana, thus it is a sustainable and profitable crop due… Continue reading Hemp Industry Growth Makes These Stocks Must-See (GENH, ACB, TLRY, CGC, IIPR)
Biotech Sector Busy Solving Major Health Crises, These Stocks May Benefit
Biotech offers investors the rare chance to invest while drugs are candidates for commercialization and before final FDA approval. There is so much biotech activity, real estate experts say there is a shortage of lab space to conduct clinical trials. Alzheimer’s, smoking addiction and Crohn’s are just some of the diseases researched. Biotech Pharmaceutical Sector… Continue reading Biotech Sector Busy Solving Major Health Crises, These Stocks May Benefit
CBD Beverages Expected to Drive Growth in Broader CBD Market (RLBD, KGKG, PURA, PAOG, HIPH)
By 2025, the CBD food and beverage market in the United States is expected to be valued at 2.65 billion U.S. dollars. CBD-infused beverages are projected to make up 64 percent of that market, at a value of 1.7 billion dollars. Consumers are flocking to CBD beverages. These particular products lack the psychoactive side effects… Continue reading CBD Beverages Expected to Drive Growth in Broader CBD Market (RLBD, KGKG, PURA, PAOG, HIPH)